In a Phase II clinical trial, exenatide, an agonist of the GLP-1 receptor, showed great protective effects in PD patients.572 NLY01, a different GLP-1 receptor agonist that can protect dopaminergic neurons from inflammatory responses elicited by glial cells,573 has been enrolled recently in a Phase II clinical trial. Here, GLP1R is linked to Parkinson disease.